GSK, Vir cleared to leap in­to PhI­II, an­gling for a spot in the Covid-19 an­ti­body race led by Lil­ly, Re­gen­eron

Six months af­ter Glax­o­SmithK­line paid $250 mil­lion for a stake in Vir Biotech­nol­o­gy and a seat at the ta­ble de­vel­op­ing an­ti­bod­ies against Covid-19, it has a Phase III drug in its hands.

The part­ners said the in­de­pen­dent da­ta mon­i­tor­ing com­mit­tee has giv­en the green light to start the fi­nal stage of clin­i­cal test­ing af­ter re­view­ing un­blind­ed safe­ty re­sults, ex­pand­ing the COMET-ICE study to more sites in North Amer­i­ca, South Amer­i­ca and Eu­rope.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER